- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01688817
The Magnitude of Effect of PCP Counseling on Participation Rate and Sedation Rate in Colonoscopy-based Screening Program
The Magnitude of Effect of Physician's Counseling on Participation Rate and Utilization of Sedation in Colonoscopy-based Colorectal Cancer Screening Program
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participation rate is one of the major factors influencing the effectiveness of screening programs. Participation rates in CRC screening, including primary colonoscopy programs, remain suboptimal. It is known that one of the strongest predictors of CRC screening participation rate is a physician, especially primary care physician (PCP), recommendation. Engaging a PCP tends to improve participation rate in organized and opportunistic cancer screening programs.
To our best knowledge there are no randomized controlled trials, dedicated specifically to assess the effect of physician's counseling on participation rate in primary colonoscopy CRC screening programs. There is also no data on the impact of physician's counseling on patient's decision to choose unsedated (not in sedation) or sedated colonoscopy.
In this study we aimed to quantitatively estimate the impact of a PCP's counseling on screening participation rate and utilization of sedation in the opportunistic primary CRC screening program when compared to the effect obtained by using a standardized information leaflet only.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 50-65 years of age
Exclusion Criteria:
- colonoscopy within last 10 years
- change in bowel habits in the previous six months
- a visible blood in stool (unless related to known hemorrhoids)
- anemia or weight loss of unknown cause
- severe comorbid conditions making subject ineligible for screening colonoscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Physician's counseling
|
Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP.
The issue was discussed during a routine medical visit according to a standardized scheme.
PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease.
A patient was told about colonoscopy-based screening program.
A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation.
According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
|
|
Active Comparator: Information leaflet
|
Patients were given leaflet on primary colonoscopy colorectal cancer screening program.
A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program
Time Frame: Six months after intervention
|
Six months after intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).
Time Frame: Six months after intervention
|
Six months after intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Jaroslaw Regula, MD, PhD, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
- Study Chair: Michal F. Kaminski, MD, PhD, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
- Principal Investigator: Michal Wiszniewski, MD, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMKP-2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
University of ChicagoVerastem, Inc.SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeWithdrawnColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal AdenocarcinomaUnited States
-
Endeavor HealthEnrolling by invitationColorectal Cancer | Colorectal Adenoma | Colorectal PolypUnited States
-
Bristol-Myers SquibbNovartisCompletedColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaUnited States, Canada, Spain, Argentina, Australia, Belgium, Czechia, Italy, Chile, Germany
Clinical Trials on Physician's counseling
-
Al-Azhar UniversityUnknownGastrointestinal Endoscopy TrainingTurkey, Singapore, Egypt, Poland, United Kingdom, United States, Belgium, Brazil, Chile, Iran, Islamic Republic of, Pakistan, Taiwan
-
Sarcoma Alliance for Research through CollaborationMemorial Sloan Kettering Cancer Center; Royal Marsden NHS Foundation TrustRecruitingClear Cell Sarcoma (CCS) | HLA-A*0201 Positive Cells PresentUnited States
-
Fudan UniversityNot yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)China
-
AkesoNot yet recruiting
-
iOMEDICO AGRecruitingCarcinoma | Ovarian Cancer | Endometrial Neoplasms | Endometrial Cancer | Ovary Neoplasm | Neoplasm, Ovarian | Carcinoma, OvarianGermany
-
Yonsei UniversityRecruitingParoxysmal Atrial FibrillationKorea, Republic of
-
iOMEDICO AGActive, not recruiting
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
Wuhan Union Hospital, ChinaRecruitingTriple-negative Breast Cancer | CadonilimabChina
-
BayerCompletedChronic Kidney Disease in Type 2 DiabetesCanada